Get the Stockscreener App
4.49
1.13%
0.05
After Hours:
4.44
-0.05
-1.11%
Lipocine Inc stock is traded at $4.49, with a volume of 16,084.
It is up +1.13% in the last 24 hours and up +22.34% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$4.44
Open:
$4.44
24h Volume:
16,084
Relative Volume:
0.49
Market Cap:
$24.01M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-1.8866
EPS:
-2.38
Net Cash Flow:
$-11.88M
1W Performance:
-1.10%
1M Performance:
+22.34%
6M Performance:
-13.65%
1Y Performance:
+50.67%
1-Day Range:
$4.31
$4.54
1-Week Range:
$4.31
$4.9565
52-Week Range:
$2.3101
$11.79
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference | State News | hjnews.com - The Herald Journal
Alliance Global Partners Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Upgraded to Buy at StockNews.com - Defense World
‘Lubber Pandhu also has strong emotions beyond cricket’ - DTNEXT
Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada
PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead
Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat
Liquidia Corp [LQDA] Investment Guide: What You Need to Know - Knox Daily
MediPharm Labs Corp. - Baystreet.ca
A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News
PLRX’s latest rating updates from top analysts. - Knox Daily
Labcorp Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat
Prudential PLC Sells 7,956 Shares of Laboratory Co. of America Holdings (NYSE:LH) - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Research Analysts Set Expectations for Pliant Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PLRX) - Defense World
Lipocine Inc. filed SEC Form 8-K: Financial Statements and Exhibits - Quantisnow
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - Kilgore News Herald
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - PR Newswire
Lipocine (NASDAQ:LPCN) Downgraded by StockNews.com to “Hold” - Defense World
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference – Company Announcement - Financial Times
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - PR Newswire
Sarcopenia Market to Grow Positively at a Paltry CAGR During - openPR
StockNews.com Lowers Lipocine (NASDAQ:LPCN) to Hold - Defense World
Lipocine (NASDAQ:LPCN) Raised to Buy at StockNews.com - Defense World
Lipocine: Q2 Earnings Snapshot - San Antonio Express-News
Lipocine: Q2 Earnings Snapshot - San Francisco Chronicle
Lipocine: Q2 Earnings Snapshot - CTPost
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 - Manchestertimes
LPCNLipocine Inc. Latest Stock News & Market Updates - StockTitan
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 - StreetInsider.com
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 - PR Newswire
Lipocine (NASDAQ:LPCN) Stock Price Passes Below Two Hundred Day Moving Average of $5.52 - Defense World
Lipocine: Q2 Earnings Snapshot - Barchart
Lipocine: Q2 Earnings Snapshot - Milton Daily Standard
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 - StockTitan
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 - Quantisnow
Lipocine to Present at 36th Annual Roth Conference - Quantisnow
Lipocine (NASDAQ:LPCN) Stock Crosses Below Two Hundred Day Moving Average of $5.48 - Defense World
Trend Tracker for (LPCN) - Stock Traders Daily
When (LPCN) Moves Investors should Listen - Stock Traders Daily
Cirrhosis FDA Approvals, Clinical Trials and Pipeline Insights - openPR
Lipocine Inc. (NASDAQ:LPCN) Sees Significant Drop in Short Interest - Defense World
Maternal Mental Health Market Will Exhibit an Impressive Expansion by 2024-2031 | Lipocine, Pfizer, Viatris, Bold Health, Glaxo Smith Kline Inc. – TIMC - TIMC
Lipocine (NASDAQ:LPCN) Stock Crosses Above 50 Day Moving Average of $6.95 - Defense World
(LPCN) Investment Analysis and Advice - Stock Traders Daily
Lipocine (NASDAQ:LPCN) Shares Cross Above 50-Day Moving Average of $6.60 - Defense World
Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference - Quantisnow
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 - Quantisnow
Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 - Quantisnow
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):